Sanofi to acquire Dynavax for $2.2B, sending shares higher by 37%
Shares of Dynavax Technologies jumped sharply in premarket trading on Wednesday after the US vaccine maker agreed to be acquired by French pharmaceutical group Sanofi in an all-cash deal valued at about $2.2 billion. Sanofi said it will pay $15.50 per share for Dynavax, representing a premium of roughly 39% to the company’s closing price
